The Library
Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin
Tools
Tools
Tools
Mulholland, P. J., Ferry, D. R., Anderson, D., Hussain, S. A., Young, Annie M., Cook, J. E., Hodgkin, E., Seymour, L. W. and Kerr, D. J. (2001) Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin. Annals of Oncology, 12 (2). pp. 245-248. doi:10.1023/A:1008372017097
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Official URL: http://dx.doi.org/10.1023/A:1008372017097
Abstract
Background: Quercetin is a naturally occurring flavonoid with many biological activities including inhibition of a number of tyrosine kinases. A phase I, dose-escalation trial of quercetin defined the maximum tolerated dose (MTD) as 1700 mg/m2 three weekly, but the vehicle, dimethyl sulphoxide (DMSO) is unsuitable for further clinical development of quercetin. Patients and methods: A water-soluble, pro-drug of quercetin (3′(N-carboxymethyl)carbomyl-3,4′,5,7-tetrahydroxyflavone), QC12 has been synthesised. Six cancer patients received 400 mg of QC12 (equivalent to 298 mg of quercetin), orally on day 1 and intravenously (i.v.) in normal saline on day 14. Results: Following oral administration of QC12 we were unable to detect QC12 or quercetin in plasma. After i.v. administration, we detected peak plasma concentrations of QC12 of 108.7 ± 41.67 μMolar (μM). A two-compartment model with mean t1/2α of 0.31 ± 0.27 hours and mean t1/2β of 0.86 ± 0.78 hours best described the concentration-time curves for QC12. The mean AUC was 44.54 ± 13.0 μM. hour and mean volume of distribution (Vd) of 10.0 ± 6.2 litres (l). Quercetin was found in all patients following i.v. infusion of QC12, with peak levels of quercetin 19.9 ± 11.8 μM. The relative bioavailability of quercetin was estimated to be 20%-25% quercetin released from QC12. Conclusions: QC12 is not orally bioavailable. This water-soluble pro-drug warrants further clinical investigation; starting with a formal phase I, IV, dose-escalation study.
| Item Type: | Journal Article | ||||
|---|---|---|---|---|---|
| Subjects: | R Medicine > R Medicine (General) | ||||
| Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Clinical Trials Unit Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||
| Journal or Publication Title: | Annals of Oncology | ||||
| Publisher: | Oxford University Press | ||||
| ISSN: | 0923-7534 | ||||
| Official Date: | 1 February 2001 | ||||
| Dates: |
|
||||
| Volume: | 12 | ||||
| Number: | 2 | ||||
| Page Range: | pp. 245-248 | ||||
| DOI: | 10.1023/A:1008372017097 | ||||
| Status: | Peer Reviewed | ||||
| Publication Status: | Published | ||||
| Access rights to Published version: | Restricted or Subscription Access |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
